AFP is still routinely used in clinical practice as a conventional and relatively highly effective promising biomarker for surveillance and diagnosis for HCC over the past decades, despite small false positive or negative rates.6, 9 Although there are some biomarkers developed, such as des‐γ‐carboxy prothrombin (DCP),18 Glypican‐3 (GPC3),19 and alpha‐fetoprotein‐L3 (AFP‐L3),20 there is room to improve the diagnostic value for HCC, partially due to technique demand.21 The gene discussed is AFP; the disease is hepatocellular carcinoma.